Precision System Science Past Earnings Performance
Past criteria checks 0/6
Precision System Science's earnings have been declining at an average annual rate of -58.6%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 5.1% per year.
Key information
-58.6%
Earnings growth rate
-58.4%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | -5.1% |
| Return on equity | -24.5% |
| Net Margin | -24.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Precision System Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,985 | -983 | 1,588 | 216 |
| 30 Jun 24 | 3,979 | -1,121 | 1,690 | 216 |
| 31 Mar 24 | 4,012 | -1,335 | 1,669 | 375 |
| 31 Dec 23 | 4,167 | -1,585 | 1,785 | 375 |
| 30 Sep 23 | 4,824 | -1,253 | 1,943 | 375 |
| 30 Jun 23 | 5,278 | -1,324 | 2,087 | 375 |
| 31 Mar 23 | 6,180 | -600 | 2,033 | 385 |
| 31 Dec 22 | 6,966 | -499 | 2,067 | 385 |
| 30 Sep 22 | 7,089 | -343 | 2,051 | 385 |
| 30 Jun 22 | 7,434 | 45 | 1,949 | 385 |
| 31 Mar 22 | 7,896 | 332 | 1,807 | 551 |
| 31 Dec 21 | 8,365 | 518 | 1,728 | 551 |
| 30 Sep 21 | 9,092 | 699 | 1,676 | 551 |
| 30 Jun 21 | 9,298 | 795 | 1,651 | 551 |
| 31 Mar 21 | 8,551 | 543 | 1,536 | 522 |
| 31 Dec 20 | 7,560 | 447 | 1,394 | 522 |
| 30 Sep 20 | 6,219 | 194 | 1,250 | 522 |
| 30 Jun 20 | 5,067 | -114 | 1,117 | 522 |
| 31 Mar 20 | 4,675 | -27 | 1,127 | 377 |
| 31 Dec 19 | 4,370 | -55 | 1,079 | 377 |
| 30 Sep 19 | 4,359 | 27 | 1,060 | 377 |
| 30 Jun 19 | 4,381 | 130 | 1,010 | 377 |
| 31 Mar 19 | 4,144 | -155 | 893 | 568 |
| 31 Dec 18 | 3,962 | -243 | 955 | 568 |
| 30 Sep 18 | 3,782 | -335 | 1,017 | 568 |
| 30 Jun 18 | 3,641 | -457 | 1,088 | 568 |
| 31 Mar 18 | 3,596 | -584 | 1,055 | 647 |
| 31 Dec 17 | 3,630 | -648 | 1,110 | 647 |
| 30 Sep 17 | 3,872 | -507 | 1,121 | 647 |
| 30 Jun 17 | 3,847 | -555 | 1,139 | 647 |
| 31 Mar 17 | 3,912 | -1,456 | 1,151 | 777 |
| 31 Dec 16 | 4,048 | -1,463 | 1,181 | 777 |
| 30 Sep 16 | 4,185 | -1,579 | 1,257 | 777 |
| 30 Jun 16 | 4,458 | -1,582 | 1,359 | 777 |
| 31 Mar 16 | 4,584 | -602 | 1,305 | 795 |
| 31 Dec 15 | 5,032 | -257 | 1,279 | 795 |
| 30 Sep 15 | 5,093 | -234 | 1,313 | 795 |
| 30 Jun 15 | 5,143 | -215 | 1,352 | 795 |
| 31 Mar 15 | 5,009 | -469 | 1,489 | 801 |
| 31 Dec 14 | 4,473 | -897 | 1,574 | 801 |
| 30 Sep 14 | 4,114 | -891 | 1,484 | 801 |
| 30 Jun 14 | 3,921 | 611 | 1,357 | 801 |
| 31 Mar 14 | 4,030 | 2,240 | 1,478 | 395 |
| 31 Dec 13 | 3,989 | 2,457 | 1,305 | 395 |
Quality Earnings: PCNE.F is currently unprofitable.
Growing Profit Margin: PCNE.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PCNE.F is unprofitable, and losses have increased over the past 5 years at a rate of 58.6% per year.
Accelerating Growth: Unable to compare PCNE.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCNE.F is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: PCNE.F has a negative Return on Equity (-24.49%), as it is currently unprofitable.